SEARCH

SEARCH BY CITATION

References

  • 1
    Chevaliez S, Pawlotsky JM. HCV genome and life cycle. In: TanS-L, ed. Hepatitis C Viruses: Genome and Molecular Biology. Horizon Bioscience, Norwich, UK, 2006; 547.
  • 2
    Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 96273.
  • 3
    Murphy DG, Chamberland J, Dandavino R, Sablon E. A new genotype of hepatitis C virus originating from central Africa. Hepatology 2007; 46 (Suppl. 1): 623A.
  • 4
    Hadziyannis SJ, Sette Jr H, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 34655.
  • 5
    Busch MP, Glynn SA, Stramer SL, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005; 45: 25464.
  • 6
    Coppola N, Pisapia R, Marrocco C, et al. Anti-HCV IgG avidity index in acute hepatitis C. J Clin Virol 2007; 40: 1105.
  • 7
    Hellstrom UB, Sylvan SP, Decker RH, Sonnerborg A. Immunoglobulin M reactivity towards the immunologically active region sp75 of the core protein of hepatitis C virus (HCV) in chronic HCV infection. J Med Virol 1993; 39: 32532.
  • 8
    Negro F, Troonen H, Michel G, et al. Lack of monomeric IgM anti-hepatitis C virus (HCV) core antibodies in patients with chronic HCV infection. J Virol Methods 1996; 60: 17982.
  • 9
    Sagnelli E, Coppola N, Marrocco C, et al. Diagnosis of HCV related acute hepatitis by serial determination of IgM to HCV: a preliminary observation. J Biol Regul Homeost Agents 2003; 17: 20710.
  • 10
    Sagnelli E, Coppola N, Marrocco C, et al. Diagnosis of hepatitis C virus related acute hepatitis by serial determination of IgM anti-HCV titres. J Hepatol 2005; 42: 64651.
  • 11
    Pawlotsky JM, Prescott L, Simmonds P, et al. Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay. J Clin Microbiol 1997; 35: 17349.
  • 12
    Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36 (Suppl. 1): S6573.
  • 13
    Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 2007; 46: 2231.
  • 14
    Sertoz RY, Erensoy S, Pas S, et al. Comparison of sequence analysis and INNO-LiPA HBV DR line probe assay in patients with chronic hepatitis B. J Chemother 2005; 17: 51420.
  • 15
    Bouchardeau F, Cantaloube JF, Chevaliez S, et al. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol 2007; 45: 11405.
  • 16
    Chevaliez S, Bouvier-Alias M, Vandervenet C, Pawlotsky JM. HCV genotype determination in clinical practice: weaknesses of assays based on the 5′noncoding region and improvement with the core-coding region. Hepatology 2007; 46 (Suppl. 1): 839A.
  • 17
    Stelzl E, Van Der Meer C, Gouw R, et al. Determination of the hepatitis C virus subtype: comparison of sequencing and reverse hybridization assays. Clin Chem Lab Med 2007; 45: 16770.
  • 18
    Verbeeck J, Stanley MJ, Shieh J, et al. Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0. J Clin Microbiol 2008; 46: 19016.
  • 19
    Lok AS, Chien D, Choo QL, et al. Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients. Hepatology 1993; 18: 497502.
  • 20
    Thio CL, Nolt KR, Astemborski J, et al. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol 2000; 38: 5757.
  • 21
    NIH Consensus Statement on Management of Hepatitis C: 2002 NIH Consens State Sci Statements 2002; 19: 146.
  • 22
    Gad RR, Males S, Makhzangy H, et al. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. Liver Int 2008; 28: 11129.
  • 23
    Berg T, Von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 108697.
  • 24
    Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 45160.
  • 25
    Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40: 12605.
  • 26
    Ferenci P, Bergholz U, Laferl H, et al. 24 weeks treatment regimen with peginterferon alpha-2a (40 kDa) (Pegasys) plus ribavirin (Copegus) in HCV genotype 1 or 4 “super-responders”. J Hepatol 2006; 44: S6.
  • 27
    Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 260917.
  • 28
    Von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 5227.
  • 29
    Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97103.
  • 30
    Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 12434.
  • 31
    Toyoda H, Kumada T, Kiriyama S, et al. Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response. Liver Int 2008 Apr 1 [Epub ahead of print].
  • 32
    Fried MW, Hadziyannis SJ, Shiffman M, Messinger D, Zeuzem S. Rapid virological response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis C virus infection. J Hepatol 2008; 48 (Suppl. 2): S5.